Anthropic just bought a biotech startup called Coefficient Bio for just over $400 million. The company was eight months old, had fewer than 10 employees, and no publicly known product or revenue. The deal was all stock, reported first by Eric Newcomer and confirmed by The Information and TechCrunch.
If this sounds expensive for a team that could fit in a conference room, keep in mind that Anthropic is currently valued at $380 billion. The deal represented 0.1% dilution. A rounding error. Their VC, Dimension Capital, is claiming a 38,513% internal rate of return on an eight-month investment.
This is the sixth chapter in a story that keeps getting stranger.
What Anthropic Bought
Coefficient Bio was founded in late 2025 by three people who came out of Genentech's computational biology division. Nathan C. Frey, the CTO, was a Group Leader and Principal ML Scientist at Genentech's Prescient Design unit, with 20+ publications in Science Advances and Nature Machine Intelligence and an ICLR Outstanding Paper Award in 2024 for generative modeling in drug discovery. Samuel Stanton, also ex-Prescient Design, led the "lab-in-the-loop" antibody design work that engineered antibodies with 3x to 100x better binding strength across four therapeutic targets. Aris Theologis, the CEO, previously ran business development at Evozyne, an AI protein design company that raised $150 million and partnered with Takeda and NVIDIA.
The stated mission was "artificial superintelligence for science." The platform was designed to draft drug R&D plans, manage clinical regulatory strategies, and identify new drug candidates. Whether any of that existed beyond a pitch deck at the time of acquisition is unclear.
The Pattern
Coefficient Bio is Anthropic's fourth acquisition in eight months.
Humanloop came first in August 2025, an LLM evaluation platform. Then Bun in December 2025, the JavaScript runtime, timed to Claude Code hitting a billion dollars. Vercept followed in February 2026, a computer-use AI startup. Now Coefficient Bio in April.
Four acquisitions. Four completely different sectors. Developer tools, programming infrastructure, computer vision, and now drug discovery. This is not a company sharpening its focus. This is a company expanding in every direction it can find talent worth buying.
The Saga So Far
In February, the Pentagon designated Anthropic a supply chain risk after the company declined to bid on military AI contracts, citing its safety principles. In March, Anthropic sued the Pentagon. Silicon Valley filed amicus briefs in support. A federal judge called the ban "Orwellian." Yesterday, a Congressional letter from Rep. Gottheimer demanded the Pentagon explain its reasoning.
Through all of that, Anthropic kept buying companies. It kept growing. It hit $19 billion in annualized recurring revenue by March. It raised $30 billion in its Series G at a $380 billion valuation. It is reportedly targeting an IPO as early as Q4 2026, potentially raising $60 billion with Goldman Sachs and JPMorgan as lead banks.
The Pentagon blacklist didn't slow anything down. If anything, the lawsuit and the "safety company under siege" narrative made Anthropic more attractive to investors, not less.
The Life Sciences Play
This acquisition didn't come out of nowhere. Anthropic launched Claude for Life Sciences in October 2025, integrating with Benchling, PubMed, and 10x Genomics. In January 2026, it announced Claude for Healthcare, HIPAA-ready tools for medical coding, claims management, and prior authorization. The Coefficient Bio team joins what Anthropic calls its "healthcare and life sciences group."
Drug discovery is a $2.6 billion average cost per approved drug spread across 10 to 15 years. If AI can compress any part of that timeline, the pricing power is enormous. For a company eyeing a $60 billion IPO, "we accelerate drug discovery" is a better investor narrative than "we make a really good chatbot."
What to Sit With
Anthropic has spent the last two months in federal court arguing it is a safety-first company that refuses to compromise its principles for government contracts. That framing earned it a federal injunction, amicus briefs from half of Silicon Valley, and Congressional scrutiny directed at its adversary.
In the same two months, it acquired a computer-use AI company, hit $19 billion in recurring revenue, raised $30 billion at a $380 billion valuation, started planning a $60 billion IPO, and bought a biotech company for $400 million.
None of that is wrong. Companies grow. But at some point the question shifts. Anthropic's safety stance made it the protagonist of this saga. Now the saga is also about a company on a pre-IPO acquisition spree, diversifying into healthcare, defense-adjacent computer use, and drug discovery while telling a federal judge that its identity is defined by restraint.
Both things might be true. But they're getting harder to hold in the same hand.
This is Chapter 6 of Laterstack's ongoing coverage of the Anthropic-Pentagon dispute. Previous chapters: Chapter 1, Chapter 2, Chapter 3, Chapter 4, Chapter 5.